Omada Health

Omada delivers virtual-first chronic care programs for prediabetes, diabetes, hypertension, and musculoskeletal conditions, combining sensors, AI coaching, and human care teams. Filed IPO May 2025, ticker OMDA. $169.8M revenue in 2024 (+38% YoY). Has programs covering GLP-1 care, diabetes, hypertension. 1,900+ employer and health plan customers.

Omada is the most enduring independent digital chronic care company; it filed for IPO in 2025, proving the category can stand alone outside of Teladoc's Livongo acquisition and showing digital therapeutics can graduate to public-market scale.

omadahealth.com Digital Therapeutics

United Statespublic · OMDA

At a glance

Total raised

Undisclosed

no public funding on record

Headcount

501-1k

approximate · public range

Headquarters

San Francisco

United States

Founded

2012

14 years active

Status

Public

Ticker · OMDA

Patents on file

USPTO grants

For subscribers

Subscribe to see the full profile

Including Funding rounds, Bull / Bear thesis, Stock + earnings, Roster changes, Patents, News, and Open roles.

Founding

50% off

/month

94 of 100 spots left

Full

$10

/month

Available once all 100 Founding Member spots are claimed.

Get full access

Already subscribed? Sign in →

Funding history

Total raised

—

Rounds tracked

No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.

Stock performance

$16.510000228881836

2026-05-22 · OMDA

Founder backgrounds

Adrian James

Co-Founder

Holds B.S. and M.S. in Mechanical Engineering from Stanford University. Prior to co-founding Omada, spent a decade at IDEO as Domain Lead for Medical Products, contributing mechanical design expertise and project leadership across a range of medical devices. Omada itself originated as a research project inside IDEO before spinning out in 2011. Served as Omada's President and helped scale the company into a leading virtual-first chronic care provider. Now serves as a Venture Partner at Necessary Ventures and sits on several health-tech boards.

Andrew DiMichele

Co-Founder

A programmer-turned-health-entrepreneur, DiMichele was the first employee at Lattice Engines (later acquired by Dun & Bradstreet), an AI-powered data analytics company. That experience — making sense of vast datasets to drive decision-making — directly informed his approach to chronic care at Omada, which combines biometric sensors, AI, and human coaching. He holds a BS in Computer Science from Columbia University. In 2011, he co-founded Omada Health alongside Adrian James and Sean Duffy, serving as its founding CTO. He later went on to co-found Bruin Health, another digital health venture focused on integrating mental and physical care.

Sean Duffy

Co-Founder & Chief Executive Officer

Holds a BS in Neuroscience from Columbia and was enrolled in Harvard's joint MD/MBA program before taking a leave of absence to start Omada. Worked at Google out of undergrad, then at IDEO's Health & Wellness group, where an internship exposed him to human-centered design in healthcare. Prior to Omada, he founded a largely automated lifestyle business around an interactive Excel training tool — an early taste of building tech-driven products at scale. He co-founded Omada in 2011 and took it public on the Nasdaq in 2024. A distinguishing feature of his leadership is a willingness to disrupt his own business model: he shifted Omada away from the standard per-member-per-month pricing to an outcomes-based model tied to clinical results, arguing that digital health companies must focus on care delivery — not just engagement or navigation — to bend the curve of chronic disease.

AI bull / bear

Bull case

Omada Health enters the public markets with a rare combination in digital health: scale, staying power, and a standalone path none of its peers managed. The company posted $169.8 million in 2024 revenue growing 38% year-over-year, backed by 1,900-plus employer and health plan customers—a book of business that generates multi-year contract visibility and high switching costs once integrated into benefits stacks. The GLP-1 care program positions Omada squarely at the center of the decade's defining metabolic health story: employers desperate to manage runaway weight-loss drug spending need wraparound behavior-change infrastructure, and Omada is one of few providers with condition-spanning programs that pair sensor data, AI coaching, and human care teams. Unlike Livongo, which lost its identity inside Teladoc, Omada goes public as a pure-play digital chronic care company at a moment when virtual-first care delivery is no longer experimental—it is embedded in enterprise benefits procurement. The IPO itself signals category maturity and gives Omada a currency to consolidate a fragmented landscape.

Bear case

Omada's IPO lands in a market that has already seen one blockbuster digital chronic care story unravel. Teladoc's Livongo acquisition became a cautionary tale: $18.5 billion turned into multi-billion-dollar impairment charges as growth decelerated and synergies failed to materialize. Investors will demand Omada prove its 38% revenue growth is durable and not simply the tailwind of pandemic-era virtual care adoption normalizing. At $169.8 million in trailing revenue, the company remains sub-scale against the administrative cost of serving 1,900-plus enterprise accounts, each requiring implementation, engagement, and outcomes reporting. GLP-1 drugs themselves pose an existential question: if pharmacotherapy proves effective enough, employer willingness to pay for adjacent behavior-change programs could shrink rather than expand. Competition from Virta Health, insurers building in-house solutions, and point-solution fatigue among benefits buyers all constrict the addressable pipeline. Without disclosed profitability or cash-flow metrics, Omada must convince public markets its unit economics improve with scale—a thesis Livongo never fully validated.

Generated by deepseek-v4-pro · May 2, 2026Refreshes quarterly · see disclosures

In the news

MobiHealthNews5/8/2026
Omada Health reports 42% revenue growth in Q1 2026 earnings
Omada Health posts 42% YoY revenue growth in Q1 2026 as a publicly traded chronic care management platform.

Watch

Leadership

Sean Duffy

Co-Founder & Chief Executive Officer

Adrian James

Co-Founder

Andrew DiMichele

Co-Founder

—

Sarah Blanchard

Chief Financial Officer

—

Carolyn Jasik

Chief Medical Officer

—

Wei-Li Shao

President

—

Nancy Vitale

Chief People Officer

—

Products

Omada for Prevention & Weight Health
A virtual program designed for individuals with prediabetes or those seeking weight management support. Participants receive a connected scale, personalized health coaching, and evidence-based curriculum grounded in CDC-recognized Diabetes Prevention Program protocols. The program combines behavioral science, data-driven insights, and human support to help members reduce their risk of developing type 2 diabetes and achieve sustained weight loss.
Omada for Diabetes
A comprehensive virtual care program for people living with type 2 diabetes. Members receive a connected glucose meter, access to Certified Diabetes Care and Education Specialists (CDCES), and personalized coaching to help manage blood sugar levels. The program integrates continuous glucose monitoring data, medication management support, and lifestyle guidance tailored to each individual's needs and health goals.
Omada for Hypertension / Heart Health
A virtual care program that helps members manage high blood pressure through connected blood pressure monitors, personalized coaching, and clinically validated protocols. The program focuses on medication adherence, dietary changes, physical activity, and stress management to help members achieve and maintain healthy blood pressure levels. Care teams work closely with members between doctor visits to track progress and adjust care plans.
Omada for Joint & Muscle Health
A digital musculoskeletal (MSK) program providing personalized at-home physical therapy and treatment for chronic pain conditions. Members receive exercise regimens designed by licensed physical therapists, along with education and coaching to manage joint and muscle issues without requiring in-person clinic visits. The program uses motion tracking and progress monitoring to adapt exercises as members improve.
Omada for GLP-1 Support
A specialized program designed to support members on GLP-1 receptor agonist medications (such as Wegovy, Ozempic, and Mounjaro). It combines medication management with lifestyle coaching, nutrition guidance, and connected devices to help members maximize the benefits of GLP-1 therapy while minimizing side effects. The program addresses weight health, diabetes management, and sustainable habit formation alongside pharmacological treatment.

Most recent patents

Omada Health, Inc.·2025-09-09
Stable Point Determination For Monitoring User Movements
US12411660
Abstract
Stable Point Determination For Monitoring User Movements
US12411660
Abstract A system generates applications based on a domain specific language (DSL). The applications allow a user to take measurements based on user movements using a client device (for example, a mobile phone) for providing to an expert. The domain specific language includes commands that cause the generated applications to perform various tasks, such as providing specific instructions to the user, starting and stopping recording, taking measurements, and so on. The system compiles the DSL specification to generate executable instructions that are deployed (for example, on a client device such as a mobile phone). The DSL specification allows users to specify virtual points based on multiple landmarks obtained from the images of the user. The DSL specification allows users to specify a point as a stable point for landmarks that are expected to be stationary but move across frames.
View on Google Patents

Open roles

View all careers ↗